DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced second-quarter 2023 financial results.
“We delivered strong growth in the second quarter, with double-digit year-over-year growth in our core business and mid-teens growth sequentially,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “This performance was driven by exceptional 46% year-over-year KRYSTEXXA sales growth as a result of strong commercial execution and the success of our immunomodulation strategy, in addition to positive and consistent trends we are generating for TEPEZZA, which reflects the success of our expansion efforts to further penetrate the TED market and reach new prescribers. We delivered impressive 76% year-over-year UPLIZNA sales growth and see a long runway ahead as we progress our two Phase 3 programs in IgG4-RD and MG. We also announced several important clinical milestones for TEPEZZA, including strong data in low CAS and long-duration TED and data from our Phase 3 clinical trial in Japan, both of which we expect to contribute to the future growth of this medicine.”
Financial Highlights |
|||||||||||||||||
| (in millions except for per share amounts and percentages) | Q2 23 |
|
Q2 22 |
|
%
|
|
YTD 23 |
|
YTD 22 |
|
%
|
||||||
| Net sales | $ |
945.0 |
$ |
876.4 |
8 |
$ |
1,777.0 |
$ |
1,761.7 |
1 |
|
||||||
| Net income |
|
127.1 |
|
61.0 |
108 |
|
181.8 |
|
265.2 |
(31 |
) |
||||||
| Non-GAAP net income |
|
280.1 |
|
253.8 |
10 |
|
474.4 |
|
569.6 |
(17 |
) |
||||||
| Adjusted EBITDA |
|
320.4 |
|
306.6 |
4 |
|
553.3 |
|
677.8 |
(18 |
) |
||||||
| Earnings per share - diluted |
|
0.54 |
|
0.26 |
108 |
|
0.78 |
|
1.12 |
(30 |
) |
||||||
| Non-GAAP earnings per share - diluted |
|
1.20 |
|
1.07 |
12 |
|
2.03 |
|
2.41 |
(16 |
) |
||||||
Second-Quarter and Year-to-Date 2023 Net Sales Results |
|||||||||||||||||
| (in millions except for percentages) | Q2 23 | Q2 22 | % Change |
YTD 23 | YTD 22 | % Change |
|||||||||||
| TEPEZZA® | $ |
445.5 |
$ |
479.8 |
(7 |
) |
$ |
850.8 |
$ |
981.3 |
(13 |
) |
|||||
| KRYSTEXXA® |
|
244.3 |
|
167.8 |
46 |
|
|
431.3 |
|
308.5 |
40 |
|
|||||
| RAVICTI® |
|
88.4 |
|
75.7 |
17 |
|
|
178.7 |
|
154.1 |
16 |
|
|||||
| UPLIZNA®(1) |
|
68.1 |
|
38.6 |
76 |
|
|
121.9 |
|
69.1 |
76 |
|
|||||
| PROCYSBI® |
|
53.1 |
|
47.7 |
11 |
|
|
103.6 |
|
97.3 |
7 |
|
|||||
| ACTIMMUNE® |
|
29.0 |
|
30.0 |
(3 |
) |
|
58.2 |
|
61.3 |
(5 |
) |
|||||
| PENNSAID 2%®(2) |
|
7.0 |
|
23.6 |
(70 |
) |
|
16.1 |
|
59.0 |
(72 |
) |
|||||
| RAYOS® |
|
8.0 |
|
11.1 |
(28 |
) |
|
13.0 |
|
24.6 |
(47 |
) |
|||||
| BUPHENYL® |
|
1.3 |
|
1.4 |
(10 |
) |
|
2.6 |
|
3.5 |
(25 |
) |
|||||
| QUINSAIRTM |
|
0.3 |
|
0.3 |
3 |
|
|
0.6 |
|
0.6 |
1 |
|
|||||
| DUEXIS® |
|
- |
|
0.1 |
(100 |
) |
|
0.1 |
|
1.2 |
(91 |
) |
|||||
| VIMOVO® |
|
- |
|
0.3 |
(100 |
) |
|
0.1 |
|
1.2 |
(91 |
) |
|||||
| Total Net Sales(3) | $ |
945.0 |
$ |
876.4 |
8 |
|
$ |
1,777.0 |
$ |
1,761.7 |
1 |
|
|||||
(1) |
Second-quarter and year-to-date 2023 UPLIZNA net sales included $15.4 million and $22.0 million, respectively, in international net sales. Second-quarter and year-to-date 2022 UPLIZNA net sales included $8.6 million and $13.8 million, respectively, in international net sales. |
|
(2) |
On May 6, 2022, Apotex Inc. initiated an at-risk launch of generic PENNSAID 2% in the United States. |
|
(3) |
Excluding the Company’s inflammation business unit (RAYOS, PENNSAID 2%, DUEXIS and VIMOVO), which was wound down at the end of 2022 due to generic competition, second-quarter year-over-year net sales growth was 11%. |
Key Growth Drivers
TEPEZZA: TEPEZZA net sales in the second quarter were $446 million, representing a 10% sequential increase compared to the first quarter of 2023 and a 7% year-over-year decline compared to the second quarter of 2022. The TEPEZZA field-force expansion initiated late in 2022 continues to drive consistent and positive momentum in the business, including increases in new prescribers, patient enrollment forms and patient starts. Through the first half of 2023, as a result of the field-force expansion, the Company expanded its reach to new physician targets, which led to a 50% year-over-year increase in the number of ophthalmologists and endocrinologists prescribing TEPEZZA. In line with the Company’s expansion strategy, prescriber growth has largely come from ophthalmologists, with continued strong referral volume from endocrinologists.
In April 2023, the Company announced positive topline results from its TEPEZZA Phase 4 clinical trial in patients with low CAS and long-duration TED and received FDA approval for an update to the indication for TEPEZZA that supports its potential benefit in TED, regardless of disease activity or duration. The Company is executing on its payer strategy to educate key stakeholders and ease the access burden so all eligible patients can benefit from TEPEZZA. As a result of this process, large national and regional payers are beginning the process of updating their access requirements. To date, the Company has obtained favorable policy changes for greater than 20% of U.S. covered lives, which are expected to take effect in the second half of 2023. The Company expects these strategies and initiatives to further develop the TED market and impact net sales in 2024.
In addition, the Company made significant advancements in its global expansion strategy by announcing the positive topline results from its TEPEZZA Phase 3 clinical trial in Japanese patients, as well as the approval of TEPEZZA in Brazil for patients with TED. There are no medicines approved for the treatment of TED in Brazil or Japan, representing a significant unmet need in both markets. These accomplishments, which are expected to impact net sales beginning in 2025, are important milestones in the Company’s global expansion strategy to bring TEPEZZA to more patients worldwide.
KRYSTEXXA: KRYSTEXXA net sales in the second quarter were a record $244 million, representing a 31% sequential increase compared to the first quarter of 2023 and a 46% year-over-year increase compared to the second quarter of 2022. KRYSTEXXA net sales are now annualizing at a nearly one-billion-dollar run rate. The second-quarter results were driven by execution across all phases of the patient journey – demand generation, stakeholder education and adherence to treatment. The Company continued to see significant uptake from both its rheumatology and nephrology market segments in the quarter, with KRYSTEXXA with immunomodulation usage now at more than 70% of new patient starts. The Company’s efforts to educate physicians and key stakeholders continues to lead to strong patient growth from both new and existing prescribers across both market segments.
UPLIZNA: UPLIZNA net sales in the second quarter were a record $68 million, representing a 27% sequential increase compared to the first quarter of 2023 and a 76% year-over-year increase compared to the second quarter of 2022. Net sales in the U.S. were $53 million, an increase of 76% year-over-year, driven by strong commercial execution. The second-quarter results were driven by robust demand generation and new patient starts, increased depth among the Company’s existing prescribers and strong adherence to maintenance treatment. The Company continues to drive uptake among both patients naïve to biologics as well as patients switching from competitive biologic therapies, establishing UPLIZNA as the fastest-growing biologic in neuromyelitis optica spectrum disorder (NMOSD) year-to-date by market share. The Company expects to advance its global expansion strategy, with multiple planned international launches in 2023. The Company also continues to make progress on its two Phase 3 programs in IgG4-related disease (IgG4-RD) and myasthenia gravis (MG).
Conference Call
In light of the announced agreement to be acquired by Amgen Inc. and applicable securities laws, the Company will not be hosting a conference call to discuss its financial results. This earnings press release, investor deck and the related Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 are publicly available in the Investor Relations section of the Company’s website at https://ir.horizontherapeutics.com.
About Horizon
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
Note Regarding Use of Non-GAAP Financial Measures
Horizon provides certain non-GAAP financial measures, including EBITDA, or earnings before interest, taxes, depreciation and amortization, adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP operating income, non-GAAP tax benefit (expense) and tax rate, non-GAAP operating cash flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon’s performance, operations, expenses, profitability and cash flows. Adjustments to Horizon’s GAAP figures exclude, as applicable, acquisition and/or divestiture-related costs, costs associated with our pending transaction with Amgen Inc., including responding to a second request review of the transaction by the United States Federal Trade Commission (the “FTC”) and subsequent lawsuit seeking to enjoin the transaction, manufacturing facility start-up costs, restructuring and realignment costs and gain on sale of asset, as well as non-cash items such as share-based compensation, inventory step-up expense, depreciation and amortization, non-cash interest expense, goodwill and long-lived assets impairment charges, gain (loss) on equity security investments and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon’s financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon’s management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the pending transaction with Amgen Inc., development, manufacturing and commercialization plans; expected timing of clinical trials and commercial launches; expected future milestones, pipeline expansions and regulatory approvals; potential market opportunities for, and benefits of, Horizon’s medicines and medicine candidates; expected impact of commercial strategies, clinical trial results and product label updates; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, whether the pending transaction with Amgen Inc. will be completed in a timely manner or at all, including whether the district court grants or denies the FTC’s request for a preliminary injunction; the parties’ ability to satisfy (or willingness to waive) the conditions to the consummation of the pending transaction with Amgen Inc., including with respect to the absence of orders preventing the consummation of the transaction; the effect of the pending transaction with Amgen Inc. on Horizon’s business relationships, operating results and business generally; risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; Horizon’s ability to grow net sales from existing medicines; impacts of the on-going war between Russia and Ukraine; changes in inflation, interest rates and general economic conditions; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; Horizon’s ability to successfully implement its business strategies, including the risks that its medicine growth and global expansion initiatives and strategies may not be successful and that new challenges to growth may arise in the future; risks inherent in developing novel medicine candidates and existing medicines for new indications; whether additional clinical trial results or data analyses will be consistent with preliminary results, results from other trials or Horizon’s expectations; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.
Horizon Therapeutics plc Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share data) |
||||||||||||||||
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||||
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||||
| Net sales | $ |
944,959 |
|
$ |
876,411 |
|
$ |
1,777,018 |
|
$ |
1,761,656 |
|
||||
| Cost of goods sold |
|
219,958 |
|
|
230,216 |
|
|
428,521 |
|
|
445,278 |
|
||||
| Gross profit |
|
725,001 |
|
|
646,195 |
|
|
1,348,497 |
|
|
1,316,378 |
|
||||
| OPERATING EXPENSES: | ||||||||||||||||
| Research and development (1) |
|
150,035 |
|
|
103,246 |
|
|
284,183 |
|
|
206,378 |
|
||||
| Selling, general and administrative |
|
434,125 |
|
|
398,221 |
|
|
887,479 |
|
|
770,955 |
|
||||
| Impairment of goodwill |
|
- |
|
|
56,171 |
|
|
- |
|
|
56,171 |
|
||||
| Gain on sale of asset |
|
(2,000 |
) |
|
- |
|
|
(2,000 |
) |
|
- |
|
||||
| Total operating expenses |
|
582,160 |
|
|
557,638 |
|
|
1,169,662 |
|
|
1,033,504 |
|
||||
| Operating income |
|
142,841 |
|
|
88,557 |
|
|
178,835 |
|
|
282,874 |
|
||||
| OTHER EXPENSE, NET: | ||||||||||||||||
| Interest expense, net |
|
(12,098 |
) |
|
(21,409 |
) |
|
(27,638 |
) |
|
(42,665 |
) |
||||
| Foreign exchange gain |
|
326 |
|
|
28 |
|
|
417 |
|
|
448 |
|
||||
| Other income (expense), net |
|
4,183 |
|
|
(2,389 |
) |
|
2,840 |
|
|
(3,131 |
) |
||||
| Total other expense, net |
|
(7,589 |
) |
|
(23,770 |
) |
|
(24,381 |
) |
|
(45,348 |
) |
||||
| Income before expense (benefit) for income taxes |
|
135,252 |
|
|
64,787 |
|
|
154,454 |
|
|
237,526 |
|
||||
| Expense (benefit) for income taxes |
|
8,181 |
|
|
3,813 |
|
|
(27,301 |
) |
|
(27,709 |
) |
||||
| Net income | $ |
127,071 |
|
$ |
60,974 |
|
$ |
181,755 |
|
$ |
265,235 |
|
||||
| Net income per ordinary share - basic | $ |
0.56 |
|
$ |
0.27 |
|
$ |
0.80 |
|
$ |
1.16 |
|
||||
| Weighted average ordinary shares outstanding - basic |
|
228,743,143 |
|
|
230,020,004 |
|
|
228,571,356 |
|
|
229,559,715 |
|
||||
| Net income per ordinary share - diluted | $ |
0.54 |
|
$ |
0.26 |
|
$ |
0.78 |
|
$ |
1.12 |
|
||||
| Weighted average ordinary shares outstanding - diluted |
|
233,935,591 |
|
|
236,166,384 |
|
|
233,938,149 |
|
|
236,077,147 |
|
||||
(1) |
Beginning with the third quarter of 2022, the Company is separately presenting upfront, milestone, and similar payments pursuant to collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development and milestones” expenses in the condensed consolidated statement of comprehensive income. Amounts recorded in this line item would have historically been recorded to research and development (“R&D”) expenses. The Company believes the new classification assists users of the financial statements in better understanding the payments incurred to acquired in-process research and development, or IPR&D. Prior period consolidated statements of comprehensive income have been reclassified to conform with the new classification. There were no acquired IPR&D and milestones expenses during the three and six months ended June 30, 2023 and 2022. |
| Horizon Therapeutics plc Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share data) |
|||||||
| As of | |||||||
| June 30, 2023 |
December 31, 2022 |
||||||
| ASSETS | |||||||
| CURRENT ASSETS: | |||||||
| Cash and cash equivalents | $ |
2,464,623 |
|
$ |
2,352,833 |
|
|
| Restricted cash |
|
4,791 |
|
|
4,755 |
|
|
| Accounts receivable, net |
|
717,417 |
|
|
676,347 |
|
|
| Inventories, net |
|
170,325 |
|
|
169,559 |
|
|
| Prepaid expenses and other current assets |
|
564,808 |
|
|
449,349 |
|
|
| Total current assets |
|
3,921,964 |
|
|
3,652,843 |
|
|
| Property, plant and equipment, net |
|
362,326 |
|
|
340,509 |
|
|
| Developed technology and other intangible assets, net |
|
2,486,565 |
|
|
2,664,777 |
|
|
| In-process research and development |
|
810,000 |
|
|
810,000 |
|
|
| Goodwill |
|
1,010,538 |
|
|
1,010,538 |
|
|
| Deferred tax assets, net |
|
444,306 |
|
|
431,814 |
|
|
| Other long-term assets |
|
263,042 |
|
|
204,135 |
|
|
| Total assets | $ |
9,298,741 |
|
$ |
9,114,616 |
|
|
| LIABILITIES AND SHAREHOLDERS' EQUITY | |||||||
| CURRENT LIABILITIES: | |||||||
| Accounts payable | $ |
85,543 |
|
$ |
155,800 |
|
|
| Accrued expenses and other current liabilities |
|
496,669 |
|
|
457,557 |
|
|
| Accrued trade discounts and rebates |
|
319,469 |
|
|
319,780 |
|
|
| Long-term debt—current portion |
|
16,000 |
|
|
16,000 |
|
|
| Total current liabilities |
|
917,681 |
|
|
949,137 |
|
|
| LONG-TERM LIABILITIES: | |||||||
| Long-term debt, net |
|
2,541,458 |
|
|
2,546,837 |
|
|
| Deferred tax liabilities, net |
|
264,815 |
|
|
342,017 |
|
|
| Other long-term liabilities |
|
263,828 |
|
|
204,451 |
|
|
| Total long-term liabilities |
|
3,070,101 |
|
|
3,093,305 |
|
|
| COMMITMENTS AND CONTINGENCIES | |||||||
| SHAREHOLDERS' EQUITY: | |||||||
| Ordinary shares, $0.0001 nominal value; 600,000,000 shares | |||||||
| authorized at June 30, 2023 and December 31, 2022; | |||||||
| 229,323,393 and 227,625,913 shares issued at June 30, 2023 | |||||||
| and December 31, 2022, respectively; and 228,939,027 and 227,241,547 shares | |||||||
| outstanding at June 30, 2023 and December 31, 2022, respectively |
|
23 |
|
|
23 |
|
|
| Treasury stock, 384,366 ordinary shares at June 30, 2023 and December 31, 2022 |
|
(4,585 |
) |
|
(4,585 |
) |
|
| Additional paid-in capital |
|
4,522,145 |
|
|
4,474,199 |
|
|
| Accumulated other comprehensive income |
|
21,612 |
|
|
12,528 |
|
|
| Retained earnings |
|
771,764 |
|
|
590,009 |
|
|
| Total shareholders' equity |
|
5,310,959 |
|
|
5,072,174 |
|
|
| Total liabilities and shareholders' equity | $ |
9,298,741 |
|
$ |
9,114,616 |
|
|
| Horizon Therapeutics plc Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) |
||||||||||||||||
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||||
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||||||||||
| Net income | $ |
127,071 |
|
$ |
60,974 |
|
$ |
181,755 |
|
$ |
265,235 |
|
||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||||
| Depreciation and amortization expense |
|
96,285 |
|
|
97,426 |
|
|
191,145 |
|
|
192,538 |
|
||||
| Equity-settled share-based compensation |
|
60,271 |
|
|
45,149 |
|
|
118,391 |
|
|
92,449 |
|
||||
| Impairment of goodwill |
|
- |
|
|
56,171 |
|
|
- |
|
|
56,171 |
|
||||
| Amortization of debt discount and deferred financing costs |
|
1,308 |
|
|
2,327 |
|
|
2,779 |
|
|
3,904 |
|
||||
| Gain on sale of asset |
|
(2,000 |
) |
|
- |
|
|
(2,000 |
) |
|
- |
|
||||
| Deferred income taxes |
|
(4,642 |
) |
|
30,864 |
|
|
(91,952 |
) |
|
(3,032 |
) |
||||
| Foreign exchange and other adjustments |
|
(5,708 |
) |
|
7,376 |
|
|
(6,143 |
) |
|
10,566 |
|
||||
| Changes in operating assets and liabilities: | ||||||||||||||||
| Accounts receivable |
|
(92,670 |
) |
|
11,152 |
|
|
(41,140 |
) |
|
(40,513 |
) |
||||
| Inventories |
|
(5,833 |
) |
|
22,818 |
|
|
(766 |
) |
|
22,033 |
|
||||
| Prepaid expenses and other current assets |
|
(60,191 |
) |
|
(38,373 |
) |
|
(108,816 |
) |
|
(71,578 |
) |
||||
| Accounts payable |
|
7,807 |
|
|
(48,047 |
) |
|
(70,233 |
) |
|
(11,980 |
) |
||||
| Accrued trade discounts and rebates |
|
9,386 |
|
|
(27,047 |
) |
|
(552 |
) |
|
20,232 |
|
||||
| Accrued expenses and other current liabilities |
|
20,532 |
|
|
36,874 |
|
|
63,390 |
|
|
(76,901 |
) |
||||
| Other non-current assets and liabilities |
|
9,851 |
|
|
(8,468 |
) |
|
11,931 |
|
|
5,863 |
|
||||
| Net cash provided by operating activities |
|
161,467 |
|
|
249,196 |
|
|
247,789 |
|
|
464,987 |
|
||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||||||||||
| Payments for acquisitions, net of cash acquired |
|
- |
|
|
- |
|
|
- |
|
|
(3,122 |
) |
||||
| Purchases of property, plant and equipment |
|
(18,466 |
) |
|
(10,154 |
) |
|
(42,594 |
) |
|
(24,352 |
) |
||||
| Payments for long-term investments |
|
(1,560 |
) |
|
(6,443 |
) |
|
(4,183 |
) |
|
(4,847 |
) |
||||
| Receipts from long-term investments |
|
- |
|
|
4,416 |
|
|
- |
|
|
4,416 |
|
||||
| Payments related to license and collaboration agreements |
|
- |
|
|
- |
|
|
(15,000 |
) |
|
(25,000 |
) |
||||
| Net cash used in investing activities |
|
(20,026 |
) |
|
(12,181 |
) |
|
(61,777 |
) |
|
(52,905 |
) |
||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||||||||||
| Repayment of term loans |
|
(4,000 |
) |
|
(4,000 |
) |
|
(8,000 |
) |
|
(8,000 |
) |
||||
| Proceeds from the issuance of ordinary shares in conjunction with ESPP program |
|
14,912 |
|
|
13,884 |
|
|
14,912 |
|
|
13,884 |
|
||||
| Proceeds from the issuance of ordinary shares in connection with stock option exercises |
|
2,628 |
|
|
12,951 |
|
|
6,049 |
|
|
22,022 |
|
||||
| Payment of employee withholding taxes relating to share-based awards |
|
(4,506 |
) |
|
(5,419 |
) |
|
(92,055 |
) |
|
(120,527 |
) |
||||
| Net cash provided by (used in) financing activities |
|
9,034 |
|
|
17,416 |
|
|
(79,094 |
) |
|
(92,621 |
) |
||||
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash |
|
2,539 |
|
|
(4,396 |
) |
|
4,908 |
|
|
(6,317 |
) |
||||
| Net increase in cash, cash equivalents and restricted cash |
|
153,014 |
|
|
250,035 |
|
|
111,826 |
|
|
313,144 |
|
||||
| Cash, cash equivalents and restricted cash, beginning of the period(1) |
|
2,316,400 |
|
|
1,647,265 |
|
|
2,357,588 |
|
|
1,584,156 |
|
||||
| Cash, cash equivalents and restricted cash, end of the period(1) | $ |
2,469,414 |
|
$ |
1,897,300 |
|
$ |
2,469,414 |
|
$ |
1,897,300 |
|
||||
(1) |
Amounts include restricted cash balance in accordance with ASU No. 2016-18. Cash and cash equivalents excluding restricted cash are shown on the balance sheet. | ||||||||||||
| Horizon Therapeutics plc
GAAP to Non-GAAP Reconciliations Net Income and Earnings Per Share (Unaudited) (in thousands, except share and per share data) |
||||||||||||||||
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||||
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||||
| GAAP net income | $ |
127,071 |
|
$ |
60,974 |
|
$ |
181,755 |
|
$ |
265,235 |
|
||||
| Non-GAAP adjustments: | ||||||||||||||||
| Acquisition/divestiture-related costs |
|
52 |
|
|
1,023 |
|
|
733 |
|
|
2,612 |
|
||||
| Transaction-related costs |
|
16,539 |
|
|
- |
|
|
26,323 |
|
|
- |
|
||||
| (Gain) loss on equity security investments |
|
(2,437 |
) |
|
438 |
|
|
(2,789 |
) |
|
5,084 |
|
||||
| Restructuring and realignment costs |
|
854 |
|
|
1,253 |
|
|
2,676 |
|
|
1,790 |
|
||||
| Manufacturing facility start-up costs |
|
1,896 |
|
|
1,582 |
|
|
5,372 |
|
|
2,389 |
|
||||
| Amortization and step-up: | ||||||||||||||||
| Intangible amortization expense |
|
89,598 |
|
|
91,335 |
|
|
178,212 |
|
|
180,595 |
|
||||
| Inventory step-up expense |
|
1,572 |
|
|
17,362 |
|
|
31,315 |
|
|
44,563 |
|
||||
| Amortization of debt discount and deferred financing costs |
|
1,308 |
|
|
2,327 |
|
|
2,779 |
|
|
3,904 |
|
||||
| Impairment of goodwill |
|
- |
|
|
56,171 |
|
|
- |
|
|
56,171 |
|
||||
| Gain on sale of asset |
|
(2,000 |
) |
|
- |
|
|
(2,000 |
) |
|
- |
|
||||
| Share-based compensation |
|
60,271 |
|
|
45,149 |
|
|
118,391 |
|
|
92,449 |
|
||||
| Depreciation |
|
6,687 |
|
|
6,091 |
|
|
12,933 |
|
|
11,943 |
|
||||
| Total of pre-tax non-GAAP adjustments |
|
174,340 |
|
|
222,731 |
|
|
373,945 |
|
|
401,500 |
|
||||
| Income tax effect of pre-tax non-GAAP adjustments |
|
(21,354 |
) |
|
(29,919 |
) |
|
(81,297 |
) |
|
(97,131 |
) |
||||
| Total of non-GAAP adjustments |
|
152,986 |
|
|
192,812 |
|
|
292,648 |
|
|
304,369 |
|
||||
| Non-GAAP net income | $ |
280,057 |
|
$ |
253,786 |
|
$ |
474,403 |
|
$ |
569,604 |
|
||||
| Non-GAAP Earnings Per Share: | ||||||||||||||||
| Weighted average ordinary shares - Basic |
|
228,743,143 |
|
|
230,020,004 |
|
|
228,571,356 |
|
|
229,559,715 |
|
||||
| Non-GAAP Earnings Per Share - Basic: | ||||||||||||||||
| GAAP earnings per share - Basic | $ |
0.56 |
|
$ |
0.27 |
|
$ |
0.80 |
|
$ |
1.16 |
|
||||
| Non-GAAP adjustments |
|
0.66 |
|
|
0.83 |
|
|
1.28 |
|
|
1.32 |
|
||||
| Non-GAAP earnings per share - Basic | $ |
1.22 |
|
$ |
1.10 |
|
$ |
2.08 |
|
$ |
2.48 |
|
||||
| Weighted average ordinary shares - Diluted | ||||||||||||||||
| Weighted average ordinary shares - Basic |
|
228,743,143 |
|
|
230,020,004 |
|
|
228,571,356 |
|
|
229,559,715 |
|
||||
| Ordinary share equivalents |
|
5,192,448 |
|
|
6,146,380 |
|
|
5,366,793 |
|
|
6,517,432 |
|
||||
| Weighted average ordinary shares - Diluted |
|
233,935,591 |
|
|
236,166,384 |
|
|
233,938,149 |
|
|
236,077,147 |
|
||||
| Non-GAAP Earnings Per Share - Diluted | ||||||||||||||||
| GAAP earnings per share - Diluted | $ |
0.54 |
|
$ |
0.26 |
|
$ |
0.78 |
|
$ |
1.12 |
|
||||
| Non-GAAP adjustments |
|
0.66 |
|
|
0.81 |
|
|
1.25 |
|
|
1.29 |
|
||||
| Non-GAAP earnings per share - Diluted | $ |
1.20 |
|
$ |
1.07 |
|
$ |
2.03 |
|
$ |
2.41 |
|
||||
| Horizon Therapeutics plc GAAP to Non-GAAP Reconciliations EBITDA and Adjusted EBITDA (Unaudited) (in thousands) |
|||||||||||||||
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|||||||||||||
2023 |
|
2022 |
|
2023 |
|
2022 |
|||||||||
| GAAP net income | $ |
127,071 |
|
$ |
60,974 |
$ |
181,755 |
|
$ |
265,235 |
|
||||
| Depreciation |
|
6,687 |
|
|
6,091 |
|
12,933 |
|
|
11,943 |
|
||||
| Amortization and step-up: | |||||||||||||||
| Intangible amortization expense |
|
89,598 |
|
|
91,335 |
|
178,212 |
|
|
180,595 |
|
||||
| Inventory step-up expense |
|
1,572 |
|
|
17,362 |
|
31,315 |
|
|
44,563 |
|
||||
| Interest expense, net (including amortization of | |||||||||||||||
| debt discount and deferred financing costs) |
|
12,098 |
|
|
21,409 |
|
27,638 |
|
|
42,665 |
|
||||
| Expense (benefit) for income taxes |
|
8,181 |
|
|
3,813 |
|
(27,301 |
) |
|
(27,709 |
) |
||||
| EBITDA | $ |
245,207 |
|
$ |
200,984 |
$ |
404,552 |
|
$ |
517,292 |
|
||||
| Other non-GAAP adjustments: | |||||||||||||||
| Share-based compensation |
|
60,271 |
|
|
45,149 |
|
118,391 |
|
|
92,449 |
|
||||
| (Gain) loss on equity security investments |
|
(2,437 |
) |
|
438 |
|
(2,789 |
) |
|
5,084 |
|
||||
| Impairment of goodwill |
|
- |
|
|
56,171 |
|
- |
|
|
56,171 |
|
||||
| Gain on sale of asset |
|
(2,000 |
) |
|
- |
|
(2,000 |
) |
|
- |
|
||||
| Acquisition/divestiture-related costs |
|
52 |
|
|
1,023 |
|
733 |
|
|
2,612 |
|
||||
| Transaction-related costs |
|
16,539 |
|
|
- |
|
26,323 |
|
|
- |
|
||||
| Manufacturing facility start-up costs |
|
1,896 |
|
|
1,582 |
|
5,372 |
|
|
2,389 |
|
||||
| Restructuring and realignment costs |
|
854 |
|
|
1,253 |
|
2,676 |
|
|
1,790 |
|
||||
| Total of other non-GAAP adjustments |
|
75,175 |
|
|
105,616 |
|
148,706 |
|
|
160,495 |
|
||||
| Adjusted EBITDA | $ |
320,382 |
|
$ |
306,600 |
$ |
553,258 |
|
$ |
677,787 |
|
||||
| Horizon Therapeutics plc GAAP to Non-GAAP Reconciliations Operating Income (Unaudited) (in thousands) |
||||||||||||||
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
2023 |
|
2022 |
|
2023 |
|
2022 |
||||||||
| GAAP operating income | $ |
142,841 |
|
$ |
88,557 |
|
$ |
178,835 |
|
$ |
282,874 |
|||
| Non-GAAP adjustments: | ||||||||||||||
| Acquisition/divestiture-related costs |
|
52 |
|
|
1,023 |
|
|
733 |
|
|
2,612 |
|||
| Transaction-related costs |
|
16,539 |
|
|
- |
|
|
26,323 |
|
|
- |
|||
| Restructuring and realignment costs |
|
854 |
|
|
1,253 |
|
|
2,676 |
|
|
1,790 |
|||
| Manufacturing facility start-up costs |
|
1,896 |
|
|
1,582 |
|
|
5,372 |
|
|
2,389 |
|||
| Amortization and step-up: | ||||||||||||||
| Intangible amortization expense |
|
89,598 |
|
|
91,335 |
|
|
178,212 |
|
|
180,595 |
|||
| Inventory step-up expense |
|
1,572 |
|
|
17,362 |
|
|
31,315 |
|
|
44,563 |
|||
| Impairment of goodwill |
|
- |
|
|
56,171 |
|
|
- |
|
|
56,171 |
|||
| Gain on sale of asset |
|
(2,000 |
) |
|
- |
|
|
(2,000 |
) |
|
- |
|||
| Share-based compensation |
|
60,271 |
|
|
45,149 |
|
|
118,391 |
|
|
92,449 |
|||
| Depreciation |
|
6,687 |
|
|
6,091 |
|
|
12,933 |
|
|
11,943 |
|||
| Total of non-GAAP adjustments |
|
175,469 |
|
|
219,966 |
|
|
373,955 |
|
|
392,512 |
|||
| Non-GAAP operating income | $ |
318,310 |
|
$ |
308,523 |
|
$ |
552,790 |
|
$ |
675,386 |
|||
| Foreign exchange gain |
|
326 |
|
|
28 |
|
|
417 |
|
|
448 |
|||
| Other income (expense), net |
|
1,746 |
|
|
(1,951 |
) |
|
51 |
|
|
1,953 |
|||
| Adjusted EBITDA | $ |
320,382 |
|
$ |
306,600 |
|
$ |
553,258 |
|
$ |
677,787 |
|||
| Horizon Therapeutics plc GAAP to Non-GAAP Reconciliations Gross Profit and Operating Cash Flow (Unaudited) (in thousands, except percentages) |
|||||||||||||||
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|||||||||||||
2023 |
|
2022 |
|
2023 |
|
2022 |
|||||||||
| Non-GAAP Gross Profit: | |||||||||||||||
| GAAP gross profit | $ |
725,001 |
|
$ |
646,195 |
|
$ |
1,348,497 |
|
$ |
1,316,378 |
|
|||
| Non-GAAP gross profit adjustments: | |||||||||||||||
| Acquisition/divestiture-related costs |
|
52 |
|
|
(119 |
) |
|
20 |
|
|
(1,423 |
) |
|||
| Intangible amortization expense |
|
89,259 |
|
|
90,439 |
|
|
177,537 |
|
|
179,164 |
|
|||
| Inventory step-up expense |
|
1,572 |
|
|
17,362 |
|
|
31,315 |
|
|
44,563 |
|
|||
| Share-based compensation |
|
3,141 |
|
|
2,294 |
|
|
5,803 |
|
|
4,471 |
|
|||
| Depreciation |
|
130 |
|
|
55 |
|
|
178 |
|
|
111 |
|
|||
| Total of Non-GAAP adjustments |
|
94,154 |
|
|
110,031 |
|
|
214,853 |
|
|
226,886 |
|
|||
| Non-GAAP gross profit | $ |
819,155 |
|
$ |
756,226 |
|
$ |
1,563,350 |
|
$ |
1,543,264 |
|
|||
| GAAP gross profit % |
|
76.7 |
% |
|
73.7 |
% |
|
75.9 |
% |
|
74.7 |
% |
|||
| Non-GAAP gross profit % |
|
86.7 |
% |
|
86.3 |
% |
|
88.0 |
% |
|
87.6 |
% |
|||
| GAAP cash provided by operating activities | $ |
161,467 |
|
$ |
249,196 |
|
$ |
247,789 |
|
$ |
464,987 |
|
|||
| Cash payments for acquisition/divestiture-related costs |
|
11 |
|
|
748 |
|
|
51 |
|
|
5,196 |
|
|||
| Cash payments for restructuring and realignment costs |
|
931 |
|
|
570 |
|
|
5,572 |
|
|
1,144 |
|
|||
| Cash payments for manufacturing facility start-up costs |
|
2,116 |
|
|
895 |
|
|
5,910 |
|
|
2,663 |
|
|||
| Cash payments for transaction-related costs |
|
14,074 |
|
|
- |
|
|
20,668 |
|
|
- |
|
|||
| Non-GAAP operating cash flow | $ |
178,599 |
|
$ |
251,409 |
|
$ |
279,990 |
|
$ |
473,990 |
|
|||
Horizon Therapeutics plc |
|||||||||||
GAAP to Non-GAAP Tax Rate Reconciliation (Unaudited) |
|||||||||||
(in millions, except percentages and per share amounts) |
|||||||||||
| Q2 2023 | |||||||||||
| Pre-tax Net Income | Income Tax Expense | Tax Rate | Net Income | Diluted Earnings Per Share | |||||||
| As reported - GAAP | $ |
135.3 |
$ |
8.2 |
|
6.0 |
% |
$ |
127.1 |
$ |
0.54 |
| Non-GAAP adjustments |
|
174.3 |
|
21.4 |
|
|
153.0 |
||||
| Non-GAAP | $ |
309.6 |
$ |
29.5 |
|
9.5 |
% |
$ |
280.1 |
$ |
1.20 |
| Q2 2022 | |||||||||||
| Pre-tax Net Income | Income Tax Expense | Tax Rate | Net Income | Diluted Earnings Per Share | |||||||
| As reported - GAAP | $ |
64.8 |
$ |
3.8 |
|
5.9 |
% |
$ |
61.0 |
$ |
0.26 |
| Non-GAAP adjustments |
|
222.7 |
|
29.9 |
|
|
192.8 |
||||
| Non-GAAP | $ |
287.5 |
$ |
33.7 |
|
11.7 |
% |
$ |
253.8 |
$ |
1.07 |
YTD 2023 |
|||||||||||
Pre-tax Net Income |
Income Tax (Benefit) Expense |
Tax Rate |
Net Income |
Diluted Earnings Per Share |
|||||||
| As reported - GAAP | $ |
154.5 |
$ |
(27.3 |
) |
(17.7 |
)% |
$ |
181.8 |
$ |
0.78 |
| Non-GAAP adjustments |
|
373.9 |
|
81.3 |
|
|
292.6 |
||||
| Non-GAAP | $ |
528.4 |
$ |
54.0 |
|
10.2 |
% |
$ |
474.4 |
$ |
2.03 |
YTD 2022 |
|||||||||||
Pre-tax Net Income |
Income Tax (Benefit) Expense |
Tax Rate |
Net Income |
Diluted Earnings Per Share |
|||||||
| As reported - GAAP | $ |
237.5 |
$ |
(27.7 |
) |
(11.7 |
)% |
$ |
265.2 |
$ |
1.12 |
| Non-GAAP adjustments |
|
401.5 |
|
97.1 |
|
|
304.4 |
||||
| Non-GAAP | $ |
639.0 |
$ |
69.4 |
|
10.9 |
% |
$ |
569.6 |
$ |
2.41 |
Horizon Therapeutics plc |
|||||||||||||||||||||
Certain Income Statement Line Items - Non-GAAP Adjusted |
|||||||||||||||||||||
For the Three Months Ended June 30, 2023 (Unaudited) |
|||||||||||||||||||||
(in thousands) |
|||||||||||||||||||||
| Cost of Goods | Research & | Selling, General | Gain on sale | Interest | Other Income | Income Tax | |||||||||||||||
| Sold | Development | & Administrative | of asset | Expense, net | (Expense), net | Expense | |||||||||||||||
| GAAP as reported | $ |
(219,958 |
) |
$ |
(150,035 |
) |
$ |
(434,125 |
) |
$ |
2,000 |
|
$ |
(12,098 |
) |
$ |
4,183 |
|
$ |
(8,181 |
) |
| Non-GAAP Adjustments: | |||||||||||||||||||||
| Acquisition/divestiture-related costs(1) |
|
52 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Transaction-related costs(2) |
|
- |
|
|
- |
|
|
16,539 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Gain on equity security investments(3) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(2,437 |
) |
|
- |
|
| Restructuring and realignment costs(4) |
|
- |
|
|
253 |
|
|
601 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Manufacturing facility start-up costs(5) |
|
- |
|
|
- |
|
|
1,896 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Amortization and step-up: | |||||||||||||||||||||
| Intangible amortization expense(6) |
|
89,259 |
|
|
- |
|
|
339 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Inventory step-up expense(7) |
|
1,572 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Amortization of debt discount and deferred financing costs(8) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
1,308 |
|
|
- |
|
|
- |
|
| Gain on sale of asset(9) |
|
- |
|
|
- |
|
|
- |
|
|
(2,000 |
) |
|
- |
|
|
- |
|
|
- |
|
| Share-based compensation(10) |
|
3,141 |
|
|
9,395 |
|
|
47,735 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Depreciation(11) |
|
130 |
|
|
588 |
|
|
5,969 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Income tax effect on pre-tax non-GAAP adjustments(12) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(21,354 |
) |
| Total of non-GAAP adjustments |
|
94,154 |
|
|
10,236 |
|
|
73,079 |
|
|
(2,000 |
) |
|
1,308 |
|
|
(2,437 |
) |
|
(21,354 |
) |
| Non-GAAP | $ |
(125,804 |
) |
$ |
(139,799 |
) |
$ |
(361,046 |
) |
$ |
- |
|
$ |
(10,790 |
) |
$ |
1,746 |
|
$ |
(29,535 |
) |
Horizon Therapeutics plc |
|
||||||||||||||||||||
Certain Income Statement Line Items - Non-GAAP Adjusted |
|
||||||||||||||||||||
For the Three Months Ended June 30, 2022 (Unaudited) |
|
||||||||||||||||||||
(in thousands) |
|
||||||||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||
|
|
|
|
|
|
|
|||||||||||||||
Cost of Goods |
Research & |
Selling, General |
Impairment of |
Interest |
Other (Expense) |
Income Tax |
|||||||||||||||
Sold |
Development |
& Administrative |
goodwill |
Expense, net |
Income, net |
Expense |
|||||||||||||||
| GAAP as reported | $ |
(230,216 |
) |
$ |
(103,246 |
) |
$ |
(398,221 |
) |
$ |
(56,171 |
) |
$ |
(21,409 |
) |
$ |
(2,389 |
) |
$ |
(3,813 |
) |
| Non-GAAP Adjustments: | |||||||||||||||||||||
| Acquisition/divestiture-related costs(1) |
|
(119 |
) |
|
- |
|
|
1,142 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Loss on equity security investments(3) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
438 |
|
|
- |
|
| Restructuring and realignment costs(4) |
|
- |
|
|
804 |
|
|
449 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Manufacturing facility start-up costs(5) |
|
- |
|
|
- |
|
|
1,582 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Amortization and step-up: | |||||||||||||||||||||
| Intangible amortization expense(6) |
|
90,439 |
|
|
- |
|
|
896 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Inventory step-up expense(7) |
|
17,362 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Amortization of debt discount and deferred financing costs(8) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
2,327 |
|
|
- |
|
|
- |
|
| Share-based compensation(10) |
|
2,294 |
|
|
6,742 |
|
|
36,113 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Depreciation(11) |
|
55 |
|
|
267 |
|
|
5,769 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Impairment of goodwill(13) |
|
- |
|
|
- |
|
|
- |
|
|
56,171 |
|
|
- |
|
|
- |
|
|
- |
|
| Income tax effect on pre-tax non-GAAP adjustments(12) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(29,919 |
) |
| Total of non-GAAP adjustments |
|
110,031 |
|
|
7,813 |
|
|
45,951 |
|
|
56,171 |
|
|
2,327 |
|
|
438 |
|
|
(29,919 |
) |
| Non-GAAP | $ |
(120,185 |
) |
$ |
(95,433 |
) |
$ |
(352,270 |
) |
$ |
- |
|
$ |
(19,082 |
) |
$ |
(1,951 |
) |
$ |
(33,732 |
) |
| Horizon Therapeutics plc | |||||||||||||||||||||
| Certain Income Statement Line Items - Non-GAAP Adjusted | |||||||||||||||||||||
| For the Six Months Ended June 30, 2023 (Unaudited) | |||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||
| Income Tax | |||||||||||||||||||||
| Cost of Goods | Research & | Selling, General | Gain on sale | Interest | Other Income | Benefit | |||||||||||||||
| Sold | Development | & Administrative | of asset | Expense, net | (Expense), net | (Expense) | |||||||||||||||
| GAAP as reported | $ |
(428,521 |
) |
$ |
(284,183 |
) |
$ |
(887,479 |
) |
$ |
2,000 |
|
$ |
(27,638 |
) |
$ |
2,840 |
|
$ |
27,301 |
|
| Non-GAAP Adjustments: | |||||||||||||||||||||
| Acquisition/divestiture-related costs(1) |
|
20 |
|
|
- |
|
|
713 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Transaction-related costs(2) |
|
- |
|
|
- |
|
|
26,323 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Gain on equity security investments(3) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(2,789 |
) |
|
- |
|
| Restructuring and realignment costs(4) |
|
- |
|
|
50 |
|
|
2,626 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Manufacturing facility start-up costs(5) |
|
- |
|
|
- |
|
|
5,372 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Amortization and step-up: | |||||||||||||||||||||
| Intangible amortization expense(6) |
|
177,537 |
|
|
- |
|
|
675 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Inventory step-up expense(7) |
|
31,315 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Amortization of debt discount and deferred financing costs(8) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
2,779 |
|
|
- |
|
|
- |
|
| Gain on sale of asset(9) |
|
- |
|
|
- |
|
|
- |
|
|
(2,000 |
) |
|
- |
|
|
- |
|
|
- |
|
| Share-based compensation(10) |
|
5,803 |
|
|
18,561 |
|
|
94,027 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Depreciation(11) |
|
178 |
|
|
971 |
|
|
11,784 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Income tax effect on pre-tax non-GAAP adjustments(12) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(81,297 |
) |
| Total of non-GAAP adjustments |
|
214,853 |
|
|
19,582 |
|
|
141,520 |
|
|
(2,000 |
) |
|
2,779 |
|
|
(2,789 |
) |
|
(81,297 |
) |
| Non-GAAP | $ |
(213,668 |
) |
$ |
(264,601 |
) |
$ |
(745,959 |
) |
$ |
- |
|
$ |
(24,859 |
) |
$ |
51 |
|
$ |
(53,996 |
) |
| Horizon Therapeutics plc | |||||||||||||||||||||
| Certain Income Statement Line Items - Non-GAAP Adjusted | |||||||||||||||||||||
| For the Six Months Ended June 30, 2022 (Unaudited) | |||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||
| Income Tax | |||||||||||||||||||||
| Cost of Goods | Research & | Selling, General | Impairment of | Interest | Other (Expense) | Benefit | |||||||||||||||
| Sold | Development | & Administrative | goodwill | Expense, net | Income, net | (Expense) | |||||||||||||||
| GAAP as reported | $ |
(445,278 |
) |
$ |
(206,378 |
) |
$ |
(770,955 |
) |
$ |
(56,171 |
) |
$ |
(42,665 |
) |
|
(3,131 |
) |
$ |
27,709 |
|
| Non-GAAP Adjustments: | |||||||||||||||||||||
| Acquisition/divestiture-related costs(1) |
|
(1,423 |
) |
|
2,000 |
|
|
2,035 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Loss on equity security investments(3) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
5,084 |
|
|
- |
|
| Restructuring and realignment costs(4) |
|
- |
|
|
804 |
|
|
986 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Manufacturing facility start-up costs(5) |
|
- |
|
|
- |
|
|
2,389 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Amortization and step-up: | |||||||||||||||||||||
| Intangible amortization expense(6) |
|
179,164 |
|
|
- |
|
|
1,431 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Inventory step-up expense(7) |
|
44,563 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Amortization of debt discount and deferred financing costs(8) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
3,904 |
|
|
- |
|
|
- |
|
| Impairment of goodwill(13) |
|
- |
|
|
- |
|
|
- |
|
|
56,171 |
|
|
- |
|
|
- |
|
|
- |
|
| Share-based compensation(10) |
|
4,471 |
|
|
15,720 |
|
|
72,258 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Depreciation(11) |
|
111 |
|
|
493 |
|
|
11,339 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| Income tax effect on pre-tax non-GAAP adjustments(12) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(97,131 |
) |
| Total of non-GAAP adjustments |
|
226,886 |
|
|
19,017 |
|
|
90,438 |
|
|
56,171 |
|
|
3,904 |
|
|
5,084 |
|
|
(97,131 |
) |
| Non-GAAP | $ |
(218,392 |
) |
$ |
(187,361 |
) |
$ |
(680,517 |
) |
$ |
- |
|
$ |
(38,761 |
) |
$ |
1,953 |
|
$ |
(69,422 |
) |
NOTES FOR CERTAIN INCOME STATEMENT LINE ITEMS - NON-GAAP
-
Primarily represents transaction and integration costs, including, advisory, legal, consulting and certain employee-related costs, incurred in connection with our acquisitions and divestitures.
-
Primarily represents transaction-related costs, including, advisory, legal, consulting and field-based employee retention costs, incurred in connection with the transaction with Amgen. The legal costs include costs incurred in responding to the FTC’s second request and subsequent lawsuit seeking to enjoin the transaction.
-
We held investments in equity securities with readily determinable fair values of $9.8 million and $8.1 million as of June 30, 2023 and 2022, respectively, which are included in other long-term assets in the condensed consolidated balance sheet. For the three and six months ended June 30, 2023, we recognized net unrealized gains of $2.4 million and $2.8 million, respectively, due to the change in fair value of these securities.
-
Primarily represents severance and consulting costs related to the wind down of our former inflammation business during 2022 and rent and maintenance charges as a result of vacating the leased Lake Forest office in the first quarter of 2021.
-
During the three months ended June 30, 2023 and 2022, we recorded $1.9 million and $1.6 million, respectively, and $5.4 million and $2.4 million for the six months ended June 30, 2023 and 2022, respectively, of manufacturing facility start-up costs related to our drug product biologics manufacturing facility in Waterford, Ireland.
-
Intangible amortization expenses are primarily associated with our developed technology related to TEPEZZA, KRYSTEXXA, RAVICTI, UPLIZNA, PROCYSBI, ACTIMMUNE, RAYOS and BUPHENYL.
-
During the three and six months ended June 30, 2023, we recognized in cost of goods sold $1.6 million and $31.3 million, respectively, for inventory step-up expense related to UPLIZNA inventory revalued in connection with the Viela Bio, Inc. acquisition. We recorded $17.4 million and $44.6 million of UPLIZNA inventory step-up expense in cost of goods sold during the three and six months ended June 30, 2022, respectively. Because inventory step-up expense is related to an acquisition, will not continue indefinitely and has a significant effect on our gross profit, gross margin percentage and net income for all affected periods, we exclude inventory step-up expense from our non-GAAP financial measures.
-
Represents amortization of debt discount and deferred financing costs associated with our debt.
-
During the six months ended June 30, 2023, gain on sale of asset represents a $2.0 million contingent consideration payment related to the sale of MIGERGOT in 2019. The contingent consideration payment was triggered during the second quarter of 2023 and it was received in July 2023.
-
Represents share-based compensation expense associated with restricted stock unit and performance stock unit grants to our employees and non-employee directors, and our employee share purchase plan.
-
Represents depreciation expense related to our property, plant, equipment, software and leasehold improvements.
-
Income tax adjustments on pre-tax non-GAAP adjustments represent the estimated income tax impact of each pre-tax non-GAAP adjustment based on the statutory income tax rate of the applicable jurisdictions for each non-GAAP adjustment.
- Our interim goodwill impairment test in the second quarter of 2022 indicated an impairment which represented the difference between the estimated fair value of the former inflammation reporting unit and its carrying value. As a result, we recognized an impairment charge of $56.2 million in June 2022 representing the full amount of goodwill for the former inflammation reporting unit.
